Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Completed · Phase 2
Conditions studied: Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
In brief
Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.
Key facts
- Study ID
- NCT02272790
- Run by
- AstraZeneca
- People needed
- 95
- Starts
- 2015-01-30
- Expected to finish
- 2023-03-08
- Last updated by the study team
- 2023-10-03
Who can join
Age: 18 and older, up to 130. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Research Site — Gilbert, Arizona, United States
- Research Site — Tucson, Arizona, United States
- Research Site — La Jolla, California, United States
- Research Site — Los Angeles, California, United States
- Research Site — San Francisco, California, United States
- Research Site — Tampa, Florida, United States
- Research Site — West Palm Beach, Florida, United States
- Research Site — Augusta, Georgia, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — Detroit, Michigan, United States
- Research Site — New York, New York, United States
- Research Site — New York, New York, United States
- Research Site — Cleveland, Ohio, United States
- Research Site — Oklahoma City, Oklahoma, United States
- Research Site — Abington, Pennsylvania, United States
- Research Site — Nashville, Tennessee, United States
- Research Site — Dallas, Texas, United States
- Research Site — Milwaukee, Wisconsin, United States
- Research Site — Toronto, Ontario, Canada
- Research Site — Amsterdam, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.